LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis GBX 444.50 -8.50 (-1.88%) As of 09/15/2026 12:29 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About Hemogenyx Pharmaceuticals Stock (LON:HEMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HEMO alerts:Sign Up Key Stats Today's Range 430.50▼ 47050-Day Range 437▼ 80652-Week Range 356▼ 1,800Volume13,790 shsAverage Volume23,823 shsMarket Capitalization£30.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom. Read More Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEMO Stock News HeadlinesHemogenyx Pharmaceuticals PLC Announces Collaboration with Cellin TechnologiesAugust 11, 2026 | theglobeandmail.comHemogenyx Pharmaceuticals Distributes 2025 Annual Report and Confirms June AGM (HEMO)June 6, 2026 | uk.finance.yahoo.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Hemogenyx Pharmaceuticals PLC Announces Notice of AGMJune 6, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Institutional FundraiseApril 28, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDAApril 14, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial UpdateMarch 31, 2026 | finance.yahoo.comSMALL-CAP WINNERS & LOSERS: Hemogenyx raises funds for phase I trialsFebruary 10, 2026 | lse.co.ukSee More Headlines HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed this year? Hemogenyx Pharmaceuticals' stock was trading at GBX 578 at the beginning of the year. Since then, HEMO shares have decreased by 23.1% and is now trading at GBX 444.50. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings data on Thursday, April, 30th. The company reported ($170.60) EPS for the quarter. How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings4/30/2026Today9/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:HEMO Previous SymbolLON:SILF CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (170.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.89 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-2,807.75% Return on Assets-37.79% Debt Debt-to-Equity Ratio167.66 Current Ratio1.38 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 217.36 per share Price / Cash Flow2.05 Book ValueGBX 0.25 per share Price / Book1,804.28Miscellaneous Outstanding Shares6,800,000Free FloatN/AMarket Cap£30.23 million OptionableNot Optionable Beta1.49 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:HEMO) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
